
Kevin Kai Hill
Examiner (ID: 633, Phone: (571)272-8036 , Office: P/1633 )
| Most Active Art Unit | 1633 |
| Art Unit(s) | 1631, 1633, 1638 |
| Total Applications | 1120 |
| Issued Applications | 329 |
| Pending Applications | 144 |
| Abandoned Applications | 670 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 18816018
[patent_doc_number] => 20230390357
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-12-07
[patent_title] => ISCHEMIA/REPERFUSION INJURY
[patent_app_type] => utility
[patent_app_number] => 18/052863
[patent_app_country] => US
[patent_app_date] => 2022-11-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14723
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18052863
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/052863 | ISCHEMIA/REPERFUSION INJURY | Nov 3, 2022 | Abandoned |
Array
(
[id] => 18939632
[patent_doc_number] => 20240034771
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-02-01
[patent_title] => METHODS AND COMPOSITIONS FOR GENERATING AN IMMUNE RESPONSE BY INDUCING CD40 AND PATTERN RECOGNITION RECEPTORS AND ADAPTORS THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/050947
[patent_app_country] => US
[patent_app_date] => 2022-10-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 46583
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 59
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18050947
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/050947 | METHODS AND COMPOSITIONS FOR GENERATING AN IMMUNE RESPONSE BY INDUCING CD40 AND PATTERN RECOGNITION RECEPTORS AND ADAPTORS THEREOF | Oct 27, 2022 | Pending |
Array
(
[id] => 18208562
[patent_doc_number] => 20230054820
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-23
[patent_title] => GENE DELIVERY SYSTEM CONTAINING RELAXIN GENE AND PHARMACEUTICAL COMPOSITION USING RELAXIN
[patent_app_type] => utility
[patent_app_number] => 17/976062
[patent_app_country] => US
[patent_app_date] => 2022-10-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12204
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17976062
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/976062 | GENE DELIVERY SYSTEM CONTAINING RELAXIN GENE AND PHARMACEUTICAL COMPOSITION USING RELAXIN | Oct 27, 2022 | Abandoned |
Array
(
[id] => 18325969
[patent_doc_number] => 20230124097
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-20
[patent_title] => ENGINEERING STEM CELL T CELLS WITH MULTIPLE T CELL RECEPTORS
[patent_app_type] => utility
[patent_app_number] => 17/965377
[patent_app_country] => US
[patent_app_date] => 2022-10-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19643
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 69
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17965377
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/965377 | ENGINEERING STEM CELL T CELLS WITH MULTIPLE T CELL RECEPTORS | Oct 12, 2022 | Pending |
Array
(
[id] => 18336436
[patent_doc_number] => 20230128385
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-27
[patent_title] => Compositions and Methods for Anti-TnMUC1 Gold CAR T-cells
[patent_app_type] => utility
[patent_app_number] => 17/934091
[patent_app_country] => US
[patent_app_date] => 2022-09-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 43271
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 204
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17934091
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/934091 | Compositions and methods for anti-TnMUC1 gold CAR t-cells | Sep 20, 2022 | Issued |
Array
(
[id] => 18404550
[patent_doc_number] => 20230165901
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-01
[patent_title] => TREATMENT OF EXCESSIVE NEOVASCULARIZATION
[patent_app_type] => utility
[patent_app_number] => 17/901424
[patent_app_country] => US
[patent_app_date] => 2022-09-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15150
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17901424
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/901424 | TREATMENT OF EXCESSIVE NEOVASCULARIZATION | Aug 31, 2022 | Pending |
Array
(
[id] => 18282389
[patent_doc_number] => 20230097861
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-30
[patent_title] => INTRACELLULAR DELIVERY OF COMPLEXES
[patent_app_type] => utility
[patent_app_number] => 17/822942
[patent_app_country] => US
[patent_app_date] => 2022-08-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23720
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17822942
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/822942 | INTRACELLULAR DELIVERY OF COMPLEXES | Aug 28, 2022 | Pending |
Array
(
[id] => 18184267
[patent_doc_number] => 20230044997
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-09
[patent_title] => SYNTHETIC, PERSISTENT RNA CONSTRUCTS AND METHODS OF USE FOR CELL REJUVENATION AND FOR TREATMENT
[patent_app_type] => utility
[patent_app_number] => 17/812711
[patent_app_country] => US
[patent_app_date] => 2022-07-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24275
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 83
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17812711
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/812711 | SYNTHETIC, PERSISTENT RNA CONSTRUCTS AND METHODS OF USE FOR CELL REJUVENATION AND FOR TREATMENT | Jul 13, 2022 | Pending |
Array
(
[id] => 18005307
[patent_doc_number] => 20220364073
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-17
[patent_title] => ENGINEERING IMMUNE ORTHOGANOL AAV AND IMMUNE STEALTH CRISPR-CAS
[patent_app_type] => utility
[patent_app_number] => 17/851972
[patent_app_country] => US
[patent_app_date] => 2022-06-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17131
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 34
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17851972
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/851972 | ENGINEERING IMMUNE ORTHOGANOL AAV AND IMMUNE STEALTH CRISPR-CAS | Jun 27, 2022 | Abandoned |
Array
(
[id] => 18294022
[patent_doc_number] => 20230103708
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-06
[patent_title] => METHODS FOR TREATING EYE DISEASE
[patent_app_type] => utility
[patent_app_number] => 17/842225
[patent_app_country] => US
[patent_app_date] => 2022-06-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26946
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17842225
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/842225 | METHODS FOR TREATING EYE DISEASE | Jun 15, 2022 | Pending |
Array
(
[id] => 18192953
[patent_doc_number] => 20230046472
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-16
[patent_title] => THERAPEUTIC CELL COMPOSITIONS AND METHODS OF MANUFACTURING AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/837093
[patent_app_country] => US
[patent_app_date] => 2022-06-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 50624
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17837093
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/837093 | THERAPEUTIC CELL COMPOSITIONS AND METHODS OF MANUFACTURING AND USE THEREOF | Jun 9, 2022 | Pending |
Array
(
[id] => 19361107
[patent_doc_number] => 20240263141
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-08
[patent_title] => Tissue Extracts and Related Methods
[patent_app_type] => utility
[patent_app_number] => 18/567470
[patent_app_country] => US
[patent_app_date] => 2022-06-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22428
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -40
[patent_words_short_claim] => 32
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18567470
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/567470 | Tissue Extracts and Related Methods | Jun 7, 2022 | Pending |
Array
(
[id] => 18056537
[patent_doc_number] => 20220387623
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-08
[patent_title] => GROWTH FACTOR RESTORATION
[patent_app_type] => utility
[patent_app_number] => 17/750224
[patent_app_country] => US
[patent_app_date] => 2022-05-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17315
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17750224
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/750224 | GROWTH FACTOR RESTORATION | May 19, 2022 | Pending |
Array
(
[id] => 17982836
[patent_doc_number] => 20220348872
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-03
[patent_title] => CHIMERIC ANTIGEN RECEPTOR ANTI-INFLAMMATORY CELLS AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 17/746362
[patent_app_country] => US
[patent_app_date] => 2022-05-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10983
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17746362
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/746362 | CHIMERIC ANTIGEN RECEPTOR ANTI-INFLAMMATORY CELLS AND METHODS OF USE | May 16, 2022 | Abandoned |
Array
(
[id] => 17830496
[patent_doc_number] => 20220267800
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-25
[patent_title] => SYNP88, A PROMOTER FOR THE EXPRESSION OF GENES
[patent_app_type] => utility
[patent_app_number] => 17/663242
[patent_app_country] => US
[patent_app_date] => 2022-05-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9382
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17663242
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/663242 | SYNP88, A PROMOTER FOR THE EXPRESSION OF GENES | May 12, 2022 | Abandoned |
Array
(
[id] => 18146232
[patent_doc_number] => 20230020089
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-01-19
[patent_title] => SHARED NEOANTIGEN VACCINES
[patent_app_type] => utility
[patent_app_number] => 17/736738
[patent_app_country] => US
[patent_app_date] => 2022-05-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 97985
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17736738
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/736738 | SHARED NEOANTIGEN VACCINES | May 3, 2022 | Pending |
Array
(
[id] => 19316835
[patent_doc_number] => 20240238375
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-07-18
[patent_title] => AAV VIRION ENCODING NEUROTROPHIC FACTOR AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/559512
[patent_app_country] => US
[patent_app_date] => 2022-05-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34134
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18559512
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/559512 | AAV VIRION ENCODING NEUROTROPHIC FACTOR AND USES THEREOF | May 3, 2022 | Pending |
Array
(
[id] => 17944432
[patent_doc_number] => 20220331449
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-10-20
[patent_title] => VESTIBULAR SUPPORTING CELL PROMOTERS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/735221
[patent_app_country] => US
[patent_app_date] => 2022-05-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26733
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17735221
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/735221 | VESTIBULAR SUPPORTING CELL PROMOTERS AND USES THEREOF | May 2, 2022 | Pending |
Array
(
[id] => 20621674
[patent_doc_number] => 12589168
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-03-31
[patent_title] => Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems
[patent_app_type] => utility
[patent_app_number] => 17/733744
[patent_app_country] => US
[patent_app_date] => 2022-04-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 14
[patent_no_of_words] => 31238
[patent_no_of_claims] => 4
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 193
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17733744
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/733744 | Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems | Apr 28, 2022 | Issued |
Array
(
[id] => 17792469
[patent_doc_number] => 20220251560
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-11
[patent_title] => METHODS FOR PRODUCING CELL POPULATIONS WITH INCREASED NUCLEIC ACID UPTAKE
[patent_app_type] => utility
[patent_app_number] => 17/732230
[patent_app_country] => US
[patent_app_date] => 2022-04-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 40597
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 160
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17732230
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/732230 | METHODS FOR PRODUCING CELL POPULATIONS WITH INCREASED NUCLEIC ACID UPTAKE | Apr 27, 2022 | Abandoned |